Trial Profile

Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis (SPECIALS)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aleeto-Darwincell (Primary) ; Aleeto-Darwincell (Primary) ; Sodium chloride
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Acronyms SPECIALS

Most Recent Events

03 Oct 2025 New trial record
19 Sep 2025 According to a DarwinCell media release, data updates about ALT001 for the treatment of amyotrophic lateral sclerosis (ALS), presented at 150th American Neurological Association Annual Meeting (ANA 2025) was successfully held in Baltimore, USA, from September 13 to 16, 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com